Clinical Trial Update: A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2/Phase 3 clinical trial evaluating oral ozanimod in pediatric patients with moderate to severe active ulcerative colitis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Ozanimod (ozanimod)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colitis, Ulcerative | Phase 2, Phase 3 | Status: RECRUITING